Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)
Close on Nov 18, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Monte Rosa Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $28.73M, down 83.9% year over year. For fiscal 2025 it was $123.67M, up 63.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.67M | +63.5% |
| FY2024 | Dec 31, 2024 | $75.62M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.97M | -61.3% |
| Q1 FY2026 | Mar 31, 2026 | $4.21M | -95.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.78M | -95.4% |
| Q3 FY2025 | Sep 30, 2025 | $12.77M | +38.5% |
| Q2 FY2025 | Jun 30, 2025 | $23.19M | +394.0% |
| Q1 FY2025 | Mar 31, 2025 | $84.93M | +7882.0% |
| Q4 FY2024 | Dec 31, 2024 | $60.65M | – |
| Q3 FY2024 | Sep 30, 2024 | $9.22M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.70M | – |
| Q1 FY2024 | Mar 31, 2024 | $1.06M | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | – |
See a number that looks wrong?